Table 2.
VGS Bacteremia Treatment Details
| VGS Bacteremia Treatment | CTX (n = 64) | PCN G (n = 30) | P Value |
|---|---|---|---|
| Hospital length of stay, median (IQR), d | 8 (5–11) | 10 (6–13) | .159 |
| Admission to ICU | 8 (12.5) | 7 (23) | .229 |
| Duration of ICU stay, median (IQR), d | 4.5 (1–9) | 6 (3–7) | .779 |
| Isolate group | |||
| S. mitis | 45 (70.3) | 18 (60) | .324 |
| S. anginosus | 8 (12.5) | 8 (27) | .095 |
| S. bovis | 2 (3.1) | 2 (7) | .592 |
| S. mutans | 5 (7.8) | 1 (3) | .661 |
| S. salivarius | 4 (6.3) | 1 (3) | 1.000 |
| Beta-lactam allergy | 14 (21.9) | 0 (0) | .004 |
| Penicillin | 13/14 (93) | N/A | N/A |
| Severe | 1/14 (7) | N/A | N/A |
| Cephalosporin | 1/14 (7) | N/A | N/A |
| Severe | 0/14 (0) | N/A | N/A |
| Source of bacteremia identified | 62 (96.9) | 25 (84) | .032 |
| Out of n = 62: | Out of n = 25: | ||
| Infective endocarditis | 41 (66) | 17 (68) | .847 |
| Prosthetic valve endocarditis | 20 (49) | 6 (35.3) | .347 |
| Skeletal | 8 (12.9) | 6 (24) | .213 |
| Skin and soft tissue | 7 (11.3) | 3 (12) | 1.000 |
| Intra-abdomina | 5 (8.1) | 0 (0) | .316 |
| Central line | 1 (1.6) | 0 (0) | 1.000 |
| Central nervous system | 2 (3.2) | 1 (4) | 1.000 |
| Pulmonary | 0 (0) | 1 (4) | .287 |
| Urinary tract | 0 (0) | 0 (0) | n/a |
| Multiple | 4 (4.8) | 3 (12) | .405 |
| Other | 2 (3.2) | 0 (0) | .045 |
| Source removal | 16/62 (25) | 12/25 (48) | .045 |
| Time to source removal, median (IQR), d | 1 (0–9) | 5 (2.25–8.50) | .277 |
| Susceptibility, susceptible + intermediate | |||
| Penicillin | 62 (96.9) | 30 (100) | 1.000 |
| Intermediate | 16/62 (25) | 4/30 (13.3) | .709 |
| Ampicillin | 61 (95.3) | 30 (100) | .549 |
| Intermediate | 9/61 (14.1) | 4/30 (13) | 1.000 |
| Ceftriaxone | 62 (96.9) | 24 (80) | .027 |
| Intermediate | 1/62 (1.6) | 1/24 (4.2) | .590 |
| Empiric therapy | |||
| Vancomycin | 57 (89.1) | 25 (83) | .512 |
| Ceftriaxone | 4 (6.3) | 0 (0) | .303 |
| Other | 3 (4.7) | 5 (17) | .105 |
| Definitive therapy | |||
| Ceftriaxone | 56 (87.5) | 0 (0) | - |
| Penicillin G | 6 (9.4) | 26 (87) | - |
| Ampicillin | 1 (1.6) | 4 (13) | - |
| Cefazolin | 1 (1.6) | 0 (0) | - |
| Infectious diseases consult | 63 (98.4) | 30 (100) | 1.000 |
| Time to consult, median (IQR), d | 2 (1–3) | 1.5 (1–2) | .826 |
| Combination therapy with gentamicin | 12 (18.8) | 13 (43) | .012 |
| Duration, median (IQR), d | 3 (1.5–13.5) | 14 (5.5–27.5) | .034 |
| Time to documented clearance of blood culture, median (IQR), d | 2 (1–3) | 1.5 (1–2) | .079 |
| Duration of total therapy, median (IQR), d | 41.5 (30–44) | 42.5 (31.75–47.25) | .334 |
| Duration of definitive therapy, median (IQR), d | 36.5 (25.25–42) | 39.5 (28–41.25) | .354 |
| Duration of treatment arm, median (IQR), d | 38 (27–43) | 39.5 (28–41.25) | .961 |
| Outpatient line accessa | 62 (97.9) | 30 (100) | 1.000 |
| PICC | 59 (95.2) | 30 (100) | .548 |
| Midline | 3/62 (4.8) | 0 (0) | .548 |
All data are expressed as No. (%) unless otherwise noted.
Abbreviations: CTX, ceftriaxone; ICU, intensive care unit; IQR, interquartile range; PCN G, penicillin G; PICC, peripherally inserted central catheter.
aOne patient completed therapy course inpatient; 1 patient completed therapy course with oral cefpodoxime.